pIPELINE
RARE DISORDERS AND INFECTIOnS DISEAsESPharmaceutical Product Pipeline
Revive is building a pharmaceutical product portfolio targeting rare disorders and infectious diseases.
PHARMACEUTICAL STRATEGY
Clinical development of Bucillamine and Psilocybin
targeting rare disorders and infectious diseases
novel Uses, formulations and delivery system
targeting FDA designations: Orphan, Fast track, breakthrough therapy and rare pediatric diseases
FORMULATION & DELIVERY TECHNOLOGY
- Delivering naturally extracted and synthetic psilocybin and cannabinoids
- PSILOCYBIN – Prescise dosed formulations i.e. capsules, sublingual spray, gel caps, effervescent tablets and oral/transmucosal strips
- Releases (rapid, controlled, sustained), improved bioavailability, no first-pass etabolism
- CANNABIDIOL – Novel combination of composites allowing for multiple delivery formats, potential synergistic and therapeutic effects
- Tannin (plant-based) – antibacterial, antifungal, antioxidant and wound healing
- Chistosan (shrimp-based) – blood-clotting and antimicrobial properties
PRODUCT PIPELINE
Bucillamine
(Oral Tablet)
(Covid-19)
Completed Phase 3
Determining next steps and international opps
Bucillamine
(Intravenous)
Rare Inflammatory Disorders
Ischemia-reperfusion
Phase 1/2
IND filing for clinical study
Diagnostic Rapid Test
Long Covid
Pre-Commerical prototype
Preparing submission for FDA approval pathway
Oral Psilocybin
(Oral Capsule)
Substance Use Disorder
Methamphetamine
Phase 1/2
Preparing end-of-Phase 2 meeting with FDA
Psilocybin
(Microneedle Patch)
Mental Illness
Depression, Anxiety
IND-enabling
IND filing for clinical study
Bucillamine
(Oral Tabelet)
Infectious Diseases
(Covid-19)
Completed Phase 3
Determining next steps and international opps
Bucillamine
(Intravenous)
Rare Inflammatory Disorders
Ischemia-reperfusion
Phase 1/2
IND filing for clinical study
Diagnostic Rapid Test
Long Covid
Pre-commercial prototype
Preparing submission for FDA approval pathway
Oral Psilocybin
(Oral Capsule)
Substance Use Disorder
Methamphetamine
Phase 1/2
Preparing end-of-Phase 2 meeting with FDA
Psilocybin
(Microneedle Patch)
Mental Illness
Depression, Anxiety
IND-enabling
IND filing for clinical study
As for its rare disease pharmaceutical product pipeline, Revive has been granted by the U.S. Food and Drug Administration (“FDA”) two orphan drug designations for cannabidiol (“CBD”) in the treatment of autoimmune hepatitis, a rare liver disease, and CBD in the prevention of ischemia and reperfusion injury (“IRI”) resulting from solid organ transplantation, such as liver, kidney, heart and lung.